Navigation Links
Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
Date:6/8/2012

NEW BRUNSWICK, N.J., June 8, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced it expects to incur a special charge in the second quarter of 2012 of approximately $600 million to increase its accrual for the potential settlement of previously disclosed civil litigation matters related to RISPERDAL® (risperidone), INVEGA® (paliperidone), NATRECOR® (nesiritide) and Omnicare, Inc.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, discussions with state and federal government representatives, which are ongoing, and there can be no assurances that a consensual resolution will be reached, when such a resolution would occur, or what the final terms of any such resolution may be; general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

 


'/>"/>
SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... The Team Type 1 Foundation, a nonprofit ... everyone affected by diabetes, announced a partnership with VeloCity, a fundraising ride benefiting Grady ... VeloCity event takes place on May 2nd and begins on the Mercedes-Benz Stadium field ...
(Date:2/19/2020)... ... February 19, 2020 , ... The swine flu (H1N1) ... foot-and-mouth disease (FMD) is a potential new outbreak. Although the U.S. has eradicated ... more than two-thirds of countries in the world, posing a risk from trading partners. ...
(Date:2/15/2020)... Fla. (PRWEB) , ... February 14, 2020 , ... ... has established an "oral-systemic” link between the organisms that cause inflammatory gum disease ... from Tampa-based ProBiora Health?? , offers new tools in the fight against ...
Breaking Medicine Technology:
(Date:2/21/2020)... ... 21, 2020 , ... Representatives with Florida-based Baby Blendy ... opening discount 0n its anti-colic portable baby bottle blender. , " Order now ... Baby Blendy LLC, a member of the Juvenile Products Manufacturers Association. "This is ...
(Date:2/21/2020)... ... February 21, 2020 , ... Cosmetic surgery continues ... Society of Plastic Surgeons (ASPS). According to the ASPS, there were 17.7-million cosmetic ... over the previous year. The American Society of Plastic Surgeons reported that some ...
(Date:2/20/2020)... ... February 20, 2020 , ... R3 Medical Training announced its next joint injection ... how to perform injections for all large and small joints along with ultrasound needle ... videos. The best opportunity is to perform injections in a supervised setting. R3 Medical ...
(Date:2/20/2020)... CLARA, Calif. (PRWEB) , ... February 20, 2020 ... ... for insurance agents, has a new release with next generation API integration ... , Launched by VisitorsCoverage Inc. in 2017, TMQuotes was the first ...
(Date:2/19/2020)... ... February 19, 2020 , ... The American ... for its new Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is the first ... residency programs. Driven by resident involvement, the curriculum has included residents in ...
Breaking Medicine News(10 mins):